COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Jaguar Health announces virtual presentation by CEO Lisa Conte at Lytham Partners Healthcare Investor Summit. Company focuses on developing plant-based medicines for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. enters U.S. licensing agreement with Future Pak, LLC for exclusive marketing rights of Mytesi® and Canalevia®-CA1, securing $18M upfront payment and potential $20M in milestone payments -
-
-
COMMUNIQUÉ DE PRESSE
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Jaguar Health announced groundbreaking results from ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure, showing significant reduction of parenteral support (PS) and potential to save lives
